Neurologic infections are global phenomena that pose a challenge for diagnosis, prevention, and treatment. The Covid-19 pandemic, which has taken the world by storm over more than two years, now seems to be receding but will remain endemic in many countries for a long time and we will continue to see new cases and publications of acute, long- and post-covid neurological manifestations including post-covid 19 vaccine manifestations.
Over time, infections such as monkeypox and Polio have made the headlines and we have decided to include information about emerging neurologic infections under this new web page. With change in environment and migration, neurologic infections remain a big public health concern for everyone.
We aim to provide peer reviewed information through this website with pertinent timely updates highlighting new developments. We will appreciate your suggestions*.
Dr Chandrashekhar Meshram
Trustee, World Federation of Neurology
Chair, Tropical and Geographical Neurology Specialty Group of WFN
* Please send to Dr Meshram at neuroblog@wfneurology.org
Prof. Avindra Nath and Dr Bridgette Jeanne Billioux Tropical and Geographical Neurology Specialty Group
5 Feb 2023
Prof. Avindra Nath and Dr Bridgette Jeanne Billioux Tropical and Geographical Neurology Specialty Group
14 Nov 2022
Prof. Avindra Nath and Dr Bridgette Jeanne Billioux Tropical and Geographical Neurology Specialty Group
10 Oct 2022
COVID-19 Resources
Covid-19 in WFN Publications |
Prof. Avindra Nath and Dr Bridgette Jeanne Billioux Tropical and Geographical Neurology Specialty Group
5 Feb 2023
For this month's update, we present some pertinent updates in the literature and news regarding the potential for neurologic invasion and persistence of SARS-CoV-2, and the possibility of these issues leading to post-acute sequelae of COVID-19 (PASC).
In the past few months, several articles have been published which provide support to the neuroinvasiveness of SARS-CoV-2, as well as its potential for viral persistence. A notable Nature article details the in-depth evaluation of 44 autopsy cases of patients with SARS-CoV-2, including cases defined as "early" (patients having died within 14 days of illness), "mid" (died between 15-30 days of illness), and "late" (died past 30 days of illness).